Pharma companies directory 2026

Pharmaceutical Companies in Bangladesh

Bangladesh is the rare least-developed economy that formulates almost all of the medicine its own patients take: local plants meet about 98% of domestic demand, and the top ten houses hold roughly seven tenths of a market that IQVIA-style audits placed near 36,600 crore taka, or about $3.3 billion, on a Q1 2025 MAT.

That self-sufficiency was engineered. The Drugs (Control) Ordinance of 1982 and the National Drug Policy of 1986 pushed multinationals out of simple formulations and handed the volume to Dhaka- and Pabna-based groups that still dominate: Square around 17.6% of audited value, Incepta about 12.6%, Beximco about 9.4%, then Healthcare Pharmaceuticals, Renata, Eskayef, Opsonin, Aristopharma, Popular and ACI. The Directorate General of Drug Administration in Mohakhali licenses the 200-plus active manufacturers, sets maximum prices, clears API imports and signs the export certificates that let Square, Beximco and a handful of peers ship into the United States, the United Kingdom, the EU, Canada and Australia — a regulated-market list almost no other LDC industry can show. WTO TRIPS flexibilities tied to least-developed status, extended for pharmaceuticals toward 2033, still let firms manufacture some on-patent molecules for home use and selected export destinations; LDC graduation is therefore the strategic clock every board is watching. Exports remain small beside the domestic book — a little over $200 million in recent fiscal years against a $3-plus billion home market — but they are the quality benchmark. More than 85% of APIs are still imported, which is why the BSCIC API Park in Munshiganj is a policy project rather than a curiosity. BioNixus keeps the roster below because these are the plants, the price-setter and the remaining affiliates that decide who owns a class in Dhaka, Chattogram, Khulna or Rajshahi.

Updated September 2026 · Directorate General of Drug Administration (DGDA) — licensed manufacturers, registered products and pricing as of September 2026 · 18 named accounts

Request a proposal for Bangladesh Browse the 18 companies

৳36,614cr

Audited domestic market on Q1 MAT 2025, about $3.3bn, up 17.3% year on year

~98%

Share of domestic medicine demand formulated by Bangladeshi plants

~71%

Combined share of the ten largest companies (Square, Incepta, Beximco and peers)

$205–213m

Pharmaceutical export earnings in recent fiscal years (EPB / industry)

Named accounts

Top pharmaceutical companies in Bangladesh

Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against Directorate General of Drug Administration (DGDA) — licensed manufacturers, registered products and pricing (as of 2026-09-04).

#	Company	HQ	Type	Therapeutic focus	Notes
01	Directorate General of Drug Administration (DGDA)	Dhaka	Government	Registration, GMP licensing, MRP control, import of APIs and export certification	Mohakhali regulator under the Ministry of Health and Family Welfare; its price decisions and CPP letters sit on the critical path of every launch and every shipment.
02	Directorate General of Health Services	Dhaka	Government	Public-hospital networks, programme buying and CMSD demand	The health-services directorate that sits above government hospitals and vertical programmes; the public counterpart beside DGDA’s price and licence work.
03	Essential Drugs Company Limited (EDCL)	Dhaka	Government	State manufacture of essential medicines for public facilities	Government factory that supplies community clinics and public hospitals at administered prices; a useful read on how thin public-tender economics have become.
04	Square Pharmaceuticals	Dhaka	Local	Broad branded-generic portfolio, regulated-market export and Kenya plant	DSE-listed leader at about 17.6% of audited domestic value; the quality and field-force benchmark, with a Pabna lifesciences site and a Nairobi factory.
05	Incepta Pharmaceuticals	Dhaka	Local	Steriles, vaccines, biologics-adjacent lines and fast generic launches	Privately held number two at about 12.6% share; the house that most often surprises incumbents with speed-to-file on new molecules.
06	Beximco Pharmaceuticals	Dhaka	Local	US-inspected generics, respiratory, anti-infectives and AIM/DSE listing	First Bangladeshi plant with US FDA approval and a dual Dhaka–London listing; still third at home even while its export story travels farther than its export mix.
07	Healthcare Pharmaceuticals	Gazipur	Local	Branded generics with aggressive share gains in chronic care	Fourth in recent MAT tables at about 7.6%; the challenger that brand teams now treat as a top-five competitive set rather than a mid-tier also-ran.
08	Renata PLC	Dhaka	Local	Human medicines, animal health and high-growth chronic portfolios	DSE-listed group whose recent growth rate outpaced several larger peers; also the animal-health adjacency that other human-only houses lack.
09	Eskayef Pharmaceuticals	Dhaka	Local	Branded generics backed by the Transcom group’s trade reach	Transcom-owned manufacturer that combines a serious plant with group logistics; consistently inside the domestic top ten.
10	ACI Limited	Dhaka	Local	Pharmaceuticals plus a wider consumer and agri conglomerate	Listed conglomerate whose medicine book sits beside consumer brands, giving it a retail muscle that pure-play pharma houses must match with reps alone.
11	Opsonin Pharma	Barishal	Local	Primary-care branded generics from a southern manufacturing base	Barishal-headquartered top-ten house with deep upazila coverage; a reminder that not every competitive set is a Dhaka story.
12	Aristopharma	Dhaka	Local	Ophthalmology, branded generics and export to Asia and Africa	Privately held company with an unusually strong eye-care franchise and an export book that BioNixus uses as a proxy for mid-tier internationalisation.
13	Popular Pharmaceuticals	Tongi	Local	Hospital injectables, anti-infectives and fast-growing generics	Tongi manufacturer that has climbed recent MAT tables faster than several established names, especially in hospital-facing lines.
14	Beacon Pharmaceuticals	Bhaluka	Local	Oncology, sterile cytotoxics and high-containment capacity	Listed oncology specialist whose Bhaluka high-containment site is the domestic reference for cytotoxic manufacturing and a frequent export-dossier talking point.
15	Sanofi Bangladesh	Dhaka	MNC	Remaining originator, vaccine and consumer-health brands	One of the few innovator affiliates that kept a Dhaka office after the 1980s localisation wave; useful as a contrast case rather than as a volume leader.
16	Novartis (Bangladesh)	Dhaka	MNC	Specialty and selected established brands	Commercial affiliate that now plays in a market whose prescription value is set by local branded generics, not by multinational field forces.
17	Dr. Reddy’s Laboratories (Bangladesh)	Dhaka	Regional	Indian-origin branded generics and in-licensed hospital lines	South Asian affiliate that competes in the sliver of the market still open to foreign branded generics after four decades of localisation policy.
18	The ACME Laboratories	Dhaka	Local	Branded generics, herbal lines and Africa / ASEAN export registrations	DSE-listed top-twelve house whose export book and herbal adjacency make it a regular due-diligence name beside the headline three.

Primary research

These are the pharmaceutical companies accounts we study in Bangladesh

Need account-level or SKU-level data for a brand in Bangladesh? BioNixus runs primary fieldwork — brand vs competitors, including the channels a dashboard averages away. Proposal ready within 48 hours of a brief.

Planning research in Bangladesh?

Primary research, market access & HEOR. Proposals within 48 hours.

BioNixus research services

How the market is structured

How DGDA pricing, medical-representative detailing and export dossiers interact

Every pack sold inside Bangladesh needs a DGDA registration and a maximum retail price; the agency also licenses factories, inspects GMP, sits on the Drug Control Committee and issues the certificates of pharmaceutical product that foreign regulators ask for. Because domestic firms already occupy the essential-medicine space, a new molecule is usually a branded generic fighting for prescription share rather than a first-to-market originator. Demand creation is still a medical-representative business: Square, Incepta, Beximco and Healthcare field thousands of reps who call on graduate physicians in Dhaka’s private chambers, the medical-college hospitals and the upazila health complexes. Manufacturers run their own depots and van fleets into some 200,000-plus retail pharmacies; there is no Zuellig-style national wholesaler that intermediates the whole trade, which is why a launch plan is a field-force and depot plan. Public procurement is a smaller, separate river: the Central Medical Stores Depot and Essential Drugs Company Limited supply government hospitals and the community-clinic network at administered prices, and winning a CMSD tender does not automatically translate into private-pharmacy share. Export is a plant-and-dossier game. Beximco was the first Bangladeshi site to win US FDA approval; Square, Incepta, Renata and Beacon have added WHO, UK MHRA, EU and other inspections that let them sell into Africa, Southeast Asia and, selectively, regulated markets. Sanofi and Novartis keep Dhaka commercial offices for the few originator and consumer brands that the 1980s policy left them, but they no longer set the competitive tempo. LDC graduation will tighten what may be copied; the firms investing in their own APIs at Munshiganj and in oncology sterile capacity at Beacon and Incepta are the ones treating that deadline as a design constraint rather than a press-release risk.

Local

Dhaka-, Pabna-, Gazipur- and Barishal-based branded-generic houses that already satisfy 98% of national demand and now treat US, UK and EU dossiers as the next competitive frontier.

Square Pharmaceuticals
Incepta Pharmaceuticals
Beximco Pharmaceuticals
Healthcare Pharmaceuticals
Renata PLC
Eskayef Pharmaceuticals
ACI Limited
Opsonin Pharma
Aristopharma
Popular Pharmaceuticals
Beacon Pharmaceuticals
The ACME Laboratories

Multinational

The thin remaining innovator offices, chiefly Sanofi and Novartis, that hold a few originator and consumer brands the 1982 ordinance never fully displaced.

Sanofi Bangladesh
Novartis (Bangladesh)

Regional

Indian and other South Asian affiliates that still register branded generics into the residual imported slice of a market otherwise closed by industrial policy.

Dr. Reddy’s Laboratories (Bangladesh)

Distributors & importers

DGDA as price-setter and export certifier, EDCL and CMSD as the public-supply channel, and the manufacturer-owned depot-and-rep networks that replace a national wholesaler.

Directorate General of Drug Administration (DGDA)
Directorate General of Health Services
Essential Drugs Company Limited (EDCL)

What is moving

What is moving the pharmaceutical market in Bangladesh

LDC graduation and the 2033 TRIPS clock

When pharmaceutical TRIPS flexibilities tighten, simple on-patent copying gets harder; boards are therefore spending on their own APIs, on regulated-market inspections and on molecules that will still be legal to make after graduation.

Chronic-care mix shift inside a 17% growth market

Anti-diabetic, cardiovascular, oncology and respiratory lines are taking a rising share of the ৳36,600-crore book, which rewards houses such as Renata, Healthcare and Beacon that invested early in those classes.

Regulated-market inspections as a quality moat

US FDA, MHRA and EU GMP letters do more than open export doors; they are also used at home as a detailing argument against mid-tier rivals that have only a DGDA licence to show.

Munshiganj API Park and import substitution on inputs

With more than 85% of APIs still bought abroad at a bill above a billion dollars, the BSCIC park is the industrial bet that could protect margins when currency or freight next shocks the cost of imported substances.

BioNixus fieldwork

How BioNixus studies pharmaceutical companies in Bangladesh

The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in Bangladesh:

MAT-to-pharmacy reconciliation in Dhaka and Chattogram for anti-diabetic and respiratory baskets, checking whether Square and Incepta share in audits matches what retailers actually buy.
CMSD and EDCL award landscaping for essential oral solids and hospital injectables, used to size the public river separately from the rep-driven private market.
Graduate-physician panels on detailing quality and brand loyalty in cardiometabolic classes, contrasting top-five houses with mid-tier climbers such as Popular and Beacon.
Export-dossier interviews with regulatory-affairs heads on US FDA, MHRA and EU inspection status and on how LDC graduation is being written into five-year plant plans.

Questions

Frequently Asked Questions

Which Bangladeshi manufacturers hold the most domestic share?

Square leads on recent MAT figures at about 17.6%, Incepta follows near 12.6%, Beximco near 9.4%, then Healthcare, Renata, Eskayef, Opsonin, Aristopharma, Popular and ACI. The top ten together hold around 71% of audited value.

What does DGDA decide that a launch team must plan around?

Registration of the finished product, approval to import each API, the maximum retail price, GMP licensing of the plant, and the export certificates foreign agencies require. A delayed MRP letter can stall a launch even when the dossier is otherwise complete.

Why is Bangladesh called a generics export powerhouse if exports are only a few hundred million dollars?

The power is quality and destination mix, not yet scale. Meeting 98% of a 170-million-person home market and then passing US, UK and EU inspections from an LDC base is the unusual fact; the dollar export line is still a small fraction of domestic sales.

Do multinational companies still matter inside Bangladesh?

As volume leaders, no. The 1982 ordinance reserved simple formulations for local firms, and that reservation held. Sanofi, Novartis and a few peers remain for specialty, vaccines and leftover consumer brands, and as possible licensors into Square or Beximco plants.

How does BioNixus research pharmaceutical companies in Bangladesh?

Prescription-share work with graduate physicians in Dhaka, Chattogram, Khulna and Rajshahi; pharmacy purchase-record audits for anti-diabetic, antibiotic and respiratory baskets; CMSD and EDCL tender reconstruction; and plant-inspection interviews on US FDA, MHRA and EU readiness ahead of LDC graduation.

Is this Bangladeshi list sorted by last year’s turnover?

Share figures in the prose come from published MAT tables, but the table itself is grouped by role — regulator and state factory, local houses, remaining affiliates — not sorted as a league. Inclusion means the name recurs in BioNixus Bangladesh work and on DGDA or DSE records.

Sources

Data sources & methodology

This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in Bangladesh. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

Primary register: Directorate General of Drug Administration (DGDA) — licensed manufacturers, registered products and pricing, consulted 2026-09-04. Company classification (Local / MNC / Regional / distributors & importers) reflects ownership and role in Bangladesh, not size.

DGDA mandate and Mohakhali public materials on registration, pricing, GMP and export certification; Drugs (Control) Ordinance 1982 and National Drug Policy lineage
Q1 MAT 2025 audited-market tables as reported by industry compilations (৳36,614 crore; Square / Incepta / Beximco shares); DSE annual reports for Square, Beximco, Renata, ACI, Beacon
Export Promotion Bureau and Invest Bangladesh figures on export value, 98% local supply and the Munshiganj API Park; UNCTAD / BAPI commentary on LDC TRIPS flexibilities
BioNixus Bangladesh prescriber, pharmacy and plant-readiness fieldwork, 2023–2026

BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

48-hour proposal

Need brand and competitor data in Bangladesh?

Physician, pharmacist and payer fieldwork on the accounts above — prescription share, formulary position and tender exposure. Proposal within 48 hours.

Planning research in Bangladesh?

Primary research, market access & HEOR. Proposals within 48 hours.

Pharmaceutical Companies in Bangladesh

Top pharmaceutical companies in Bangladesh

These are the pharmaceutical companies accounts we study in Bangladesh

Planning research in Bangladesh?

How DGDA pricing, medical-representative detailing and export dossiers interact

Local

Multinational

Regional

Distributors & importers

What is moving the pharmaceutical market in Bangladesh

LDC graduation and the 2033 TRIPS clock

Chronic-care mix shift inside a 17% growth market

Regulated-market inspections as a quality moat

Munshiganj API Park and import substitution on inputs

How BioNixus studies pharmaceutical companies in Bangladesh

Related research and directories

Frequently Asked Questions

Data sources & methodology

Need brand and competitor data in Bangladesh?

Planning research in Bangladesh?